Status: Recruiting
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
This study aims to evaluate the efficacy and safety of Cretostimogene in patients with BCG-unresponsive high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without Ta/T1 papillary tumors.
Participants needed: 16
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Lepu Biopharma Co., Ltd.Updated: Apr 23, 2026Locations: 14
Eligibility criteria
Be ≥18 years of age on day of signing informed consent. [+5]
Has current or past history of muscle invasive (T2 or higher stage) or locally a... [+5]